JP2024517431A5 - - Google Patents
Info
- Publication number
- JP2024517431A5 JP2024517431A5 JP2023565206A JP2023565206A JP2024517431A5 JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5 JP 2023565206 A JP2023565206 A JP 2023565206A JP 2023565206 A JP2023565206 A JP 2023565206A JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- powder diffraction
- solid
- exhibiting
- solid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178752P | 2021-04-23 | 2021-04-23 | |
| US63/178,752 | 2021-04-23 | ||
| PCT/US2022/025815 WO2022226221A1 (en) | 2021-04-23 | 2022-04-21 | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517431A JP2024517431A (ja) | 2024-04-22 |
| JP2024517431A5 true JP2024517431A5 (enExample) | 2025-05-02 |
| JP7825636B2 JP7825636B2 (ja) | 2026-03-06 |
Family
ID=83723159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565206A Active JP7825636B2 (ja) | 2021-04-23 | 2022-04-21 | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208931A1 (enExample) |
| EP (1) | EP4326255A4 (enExample) |
| JP (1) | JP7825636B2 (enExample) |
| KR (1) | KR20240000540A (enExample) |
| CN (1) | CN117529313A (enExample) |
| AU (1) | AU2022261159A1 (enExample) |
| BR (1) | BR112023021916A2 (enExample) |
| CA (1) | CA3216258A1 (enExample) |
| IL (1) | IL307910A (enExample) |
| MX (1) | MX2023012521A (enExample) |
| WO (1) | WO2022226221A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| EP4326256A4 (en) | 2021-04-23 | 2025-03-19 | Pierre Fabre Medicament | Treating cancer with a RAF inhibition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| BR112021001406A2 (pt) * | 2018-07-31 | 2021-04-27 | AusCann Group Holdings Ltd | composições farmacêuticas auto-emulsificantes sólidas |
| CN113874381A (zh) | 2019-03-22 | 2021-12-31 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| AR118826A1 (es) * | 2019-05-03 | 2021-11-03 | Kinnate Biopharma Inc | Inhibidores de cinasas raf |
| BR112022007612A2 (pt) * | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
-
2022
- 2022-04-21 IL IL307910A patent/IL307910A/en unknown
- 2022-04-21 KR KR1020237039724A patent/KR20240000540A/ko active Pending
- 2022-04-21 WO PCT/US2022/025815 patent/WO2022226221A1/en not_active Ceased
- 2022-04-21 JP JP2023565206A patent/JP7825636B2/ja active Active
- 2022-04-21 US US18/556,243 patent/US20240208931A1/en active Pending
- 2022-04-21 BR BR112023021916A patent/BR112023021916A2/pt unknown
- 2022-04-21 EP EP22792520.3A patent/EP4326255A4/en active Pending
- 2022-04-21 CN CN202280044060.6A patent/CN117529313A/zh active Pending
- 2022-04-21 AU AU2022261159A patent/AU2022261159A1/en active Pending
- 2022-04-21 CA CA3216258A patent/CA3216258A1/en active Pending
- 2022-04-21 MX MX2023012521A patent/MX2023012521A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU652046B2 (en) | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | |
| JP4931874B2 (ja) | リモナバントの結晶多形の製造方法 | |
| US20090092669A1 (en) | Stable imatinib compositions | |
| US10189860B2 (en) | Hydrates of dolutegravir sodium | |
| JP2018168180A (ja) | バルサルタンおよびａｈｕ−３７７を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法 | |
| US20100010098A1 (en) | Polymorphs of rasagiline hydrochloride | |
| WO1996036595A1 (en) | 3,4-disubstituted-phenylsulphonamides and their therapeutic use | |
| EP1286670A2 (en) | Use of therapeutic benzamide derivatives | |
| KR20100126238A (ko) | Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물 | |
| JP2022532404A5 (enExample) | ||
| JP2000500732A (ja) | ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体 | |
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| JP2023548160A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物 | |
| JP7825636B2 (ja) | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 | |
| JP2007509143A5 (enExample) | ||
| CN116869915A (zh) | 含有苯并咪唑衍生物的新型制剂 | |
| PL183867B1 (pl) | Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny | |
| AU2017254950B2 (en) | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | |
| JP4278652B2 (ja) | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 | |
| JP2021529805A5 (enExample) | ||
| TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
| JP2024542840A5 (enExample) | ||
| HUP0402553A2 (hu) | Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP7226697B2 (ja) | ブロナンセリン含有錠剤 | |
| WO2013139387A1 (en) | Stabilized pharmaceutical compositions comprising rasagiline salts |